IPO Profile: TRACON Pharmaceuticals Inc

Company Details

San Diego



Description: TRACON Pharmaceuticals is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of targeted therapeutics for cancer, age-related macular degeneration(AMD) and fibrotic diseases. The company is engaged in the field of endoglin biology and develops antibodies that bind to the endoglin receptor. The company’s lead product candidate, TRC105, is an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF), pathway. Its other product candidates are TRC205, an anti-endoglin antibody that is in preclinical development for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

IPO Details

Exchange and Ticker: TCON: Nasdaq

Filing Range: 3.60 million shares @ $12.00 to $14.00

Offering Price: $10.00

Close Price as of 1/30/15: $9.40

Offering Size: $36 million

Shares Outstanding: 11.9 million

Underwriters: Wells Fargo Securities LLC, Stifel Nicolaus & Co Inc

Co-managers: Needham & Co LLC, Oppenheimer & Co Inc

Company Counsel: Cooley LLP

Manager Counsel: Latham & Watkins

Auditor: Ernst & Young LLP

Market Capitalization on 01/30/15: $112.59 million

Close Price on 1/30/15: $9.40

Investment Details

Venture Backers:

  • New Enterprise Associates
  • Nextech Invest AG
  • BHP Billiton Ventures
  • Jafco Co Ltd
  • Arcus Ventures

Financing Rounds:

  • 3/31/11 $14M
  • 9/22/14 $27M

Source: Data provided by Thomson Reuters.